Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger

AdvanCell CEO Philina Lee (L) with colleagues July 15, 2026 11:25 AM EDT Financing Ra­dio­phar­ma mak­er Ad­van­Cell hauls in $315M for Plu­vic­to chal­lenger Lei Lei Wu News Reporter Ad­van­Cell raised a $315 mil­lion Se­ries D to study a lead-based prostate can­cer agent and shore up its US man­u­fac­tur­ing of the ra­dioac­tive treat­ment. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER